Peptide legal status tracker
What can be prescribed today, what's waiting on the FDA, and what has no lawful route.
A linked source is not a clinical endorsement. How we handle review and corrections.
Every peptide
| Peptide | What people take it for | Legal status | At Goodmorrow |
|---|---|---|---|
| Tesamorelin | Belly fat | FDA-approved | Offered when we open |
| Bremelanotide | Sexual desire | FDA-approved | Offered when we open |
| GHK-Cu | Skin and hair | Compoundable | Offered when we open |
| Sermorelin | Sleep, recovery and body composition | Compoundable | Offered when we open |
| NAD+ | Energy | Compoundable | Offered when we open |
| BPC-157 | Injury and gut repair | Awaiting final rule | Waitlist open |
| TB-500 | Soft-tissue recovery | Awaiting final rule | Waitlist open |
| KPV | Inflammation | Awaiting final rule | Waitlist open |
| MOTS-c | Metabolism | Awaiting final rule | Waitlist open |
| Semax | Focus | Awaiting final rule | Waitlist open |
| Epitalon | Sleep and longevity | Awaiting final rule | Waitlist open |
| Melanotan II | Tanning | Awaiting review | Not offered |
| CJC-1295 and ipamorelin | Growth hormone | No lawful route | We offer an alternative |
| Thymosin alpha-1 | Immune support | No lawful route | Not offered |
| AOD-9604 | Fat loss | No lawful route | We offer an alternative |
| DSIP | Sleep | Rejected | Not offered |
| LL-37 | Off the restricted list in April 2026. FDA review due by February 2027. | Awaiting review | Not offered |
| Dihexa | Off the restricted list in April 2026. FDA review due by February 2027. | Awaiting review | Not offered |
| PEG-MGF | Off the restricted list in April 2026. FDA review due by February 2027. | Awaiting review | Not offered |
| Selank | Named as a candidate to return in early 2026. Not yet reviewed. | No lawful route | Not offered |
What the labels mean
- FDA-approved drug
- An approved drug with an FDA label. Can be prescribed, including off-label.
- Compoundable now
- A licensed pharmacy can compound it for a patient with a prescription.
- Backed by FDA advisers, awaiting final rule
- FDA advisers voted for it in July 2026. Not compoundable until the FDA publishes a final rule.
- Awaiting FDA review
- Off the restricted list but not on the allowed one. A review is scheduled before the end of February 2027.
- No lawful route today
- No lawful compounding route and no scheduled review.
- Rejected by FDA advisers
- FDA advisers voted against it.
How we got here
September 29, 2023
The FDA places BPC-157 and roughly 17 other peptides in Category 2, its list of bulk ingredients with significant safety concerns. Licensed pharmacies stop compounding them.
February 27, 2026
Health Secretary Robert F. Kennedy Jr. says about 14 of the 19 restricted peptides will move back toward compounding.
April 15, 2026
The FDA announces that nominations for 12 peptides were withdrawn, removing them from Category 2 effective April 22. Removal doesn't make them compoundable; it leaves them on neither list.
May 14, 2026
Non-injectable GHK-Cu, including topical forms, returns to Category 1 after its nominator clarifies it meant to withdraw only the injectable nomination.
July 23, 2026
FDA advisers vote 8 to 6 to recommend BPC-157, KPV and TB-500, and 7 to 5 for MOTS-c, overruling the FDA's own scientists.
July 24, 2026
Advisers back epitalon 7 to 4 and Semax 8 to 5, and reject DSIP (emideltide) 7 to 6.
Next
The FDA must publish a final rule before pharmacies can compound the six recommended peptides. A second review, due before the end of February 2027, covers injectable GHK-Cu, Melanotan II, LL-37, Dihexa and PEG-MGF.
Hear when the FDA acts
One text when the rule is final and we can prescribe. Nothing else.
Questions people ask
Is BPC-157 legal now?
Not for compounding. The July 2026 vote was a recommendation. Until the FDA finalizes it, licensed pharmacies can't make BPC-157 for patients.
What does Category 1 mean?
It's the FDA's interim list of bulk ingredients that pharmacies can compound with while the agency evaluates them. Category 2 is the list flagged for significant safety concerns. A peptide on neither list can't be compounded under the usual rules.
Is a PCAC recommendation the same as FDA approval?
No. The Pharmacy Compounding Advisory Committee advises the FDA, which isn't bound by its votes. Even after a final rule, a compoundable peptide isn't an FDA-approved drug.
How often is this page updated?
Whenever the FDA acts. The date at the top is the last time we checked every entry.
Sources
- Secondary sourceFDA Peptide Update 2026: Removal from the Do Not Compound List Frier Levitt, August 2026
- Secondary sourceThe Peptide Reclassification Everyone's Talking About: A Pharmacist's Take Pharmacy Times, 2026
- FDA documentJuly 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, July 2026
- Secondary sourceFDA Panel Votes to Loosen Restrictions for Four Peptides PharmExec, July 2026
- Secondary sourceFDA advisory panel narrowly rejects compounding of one peptide, backs two others STAT, July 24, 2026
- Secondary sourceFDA advisory committee nominates six peptides for pharmacies to compound National Community Pharmacists Association, July 31, 2026
- Secondary sourceBulk-list bound? PCAC backs majority of peptides in two-day public meeting McDermott Will & Schulte, July 28, 2026
- Secondary sourceThe US Peptide Status Index Peptide America
Good days ahead.
Join the opening list for appointment updates.